We are pioneering a breakthrough in the treatment of iron deficiency — one of the most widespread and under-treated health conditions globally — with a patented, side-effect-free innovation that starts with a major, high-risk patient group: those suffering from heart failure.

Our granted patent covers the treatment of iron deficiency in heart failure patients, a population where low iron levels are directly linked to worsened fatigue, decreased physical capacity, and significantly poorer outcomes. This gives us a strong, medically urgent, and IP-protected entry point into a critical segment of modern healthcare.

Building on this foundation, we are actively expanding our patent portfolio to cover women, men, and later children — where, in some regions, up to 40% of children are affected by low iron levels. Notably, 17.5% of all men globally also suffer from iron deficiency, yet the condition is often undiagnosed and untreated due to the limitations and side effects of existing therapies. Each of these target groups represents a massive, underserved market with urgent clinical need.

What makes our innovation truly unique is that it is completely free of side effects — unlike traditional iron supplements, which often cause gastrointestinal issues, poor adherence, and long-term complications. This positions us at the forefront of a new generation of well-tolerated, effective treatments — making it easier for physicians to prescribe and for patients to complete treatment.

This strategy follows the proven method of building a patent wall — a deliberate process of protecting and expanding innovation by filing multiple, related patents around a central technology. By securing IP protection across diverse patient groups and treatment applications, we create strong market barriers, increase our competitive defensibility, and multiply our commercial value.

The global market for iron treatments and supplements is currently worth over $10 billion, and is growing steadily due to aging populations, increased focus on preventive healthcare, and the widespread prevalence of iron deficiency — particularly among women, men (17.5%), and children (up to 40% in some regions). Despite this, innovation in the field remains limited — and that’s exactly where we are breaking new ground.

To unlock the full potential of our innovation and scale globally, we are preparing for a listing on the New York Stock Exchange (NYSE). A NYSE listing will provide access to institutional capital, global investor visibility, and a highly experienced base of biotech and healthcare investors. This will empower us to accelerate clinical development, expand our patent portfolio, and bring our solution to market across multiple geographies and demographics.

In short, we are redefining how the world treats iron deficiency — starting with heart failure and expanding to the broader population. We offer investors a rare opportunity to be part of a high-growth, IP-driven medical company with real-world clinical value, scalable global impact, and a clear path to long-term market leadership.